Johnson & Johnson
JNJ: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$492.00 | Bdmrw | Vnmwkgw |
Johnson & Johnson Earnings: Growth Outlook Slowing After Solid 2023, but Pipeline Holds Upside
Johnson & Johnson reported fourth-quarter results largely in line with our projections, and we are holding firm to our $164 fair value estimate. The stock looks slightly undervalued, as the market is likely not fully appreciating the firm’s long-term potential with pipeline products that also reinforce J&J’s wide moat.